Ensysce Proxy Supplement: Brokers Gain Discretionary Votes on Reverse Split; Staged Meeting Possible
ENSC sits 59% above its 52-week low of $0.23 on light trading volume (0.3× avg).
Summary
Ensysce supplemented its proxy to allow brokers to vote street-name shares on the reverse split without instructions and flagged a possible staged annual meeting, since Nasdaq requires a $4.00 bid price before the Series C conversion can close.
Key Events · Corporate Governance and Compliance · ENSC
-
Broker Discretion on Reverse Split
The supplement reverses prior disclosure: brokers will have discretionary authority to vote street-name shares on Proposal 2 even without client instructions, raising the chance the reverse split passes.
-
Staged Meeting Possible
Ensysce may vote the reverse split first and adjourn the December 14, 2026 annual meeting before the remaining proposals, then reconvene once Nasdaq initial listing requirements are met.
-
Nasdaq $4.00 Bid Price Condition
Nasdaq treats approval of Proposal 1 (Series C conversion) as a change of control under Rules 5110(a) and 5635(b), so the company must satisfy a $4.00 minimum bid price before converting the preferred.
-
Delisting Deadline February 22, 2027
The company remains below the $1.00 minimum bid price; Nasdaq extended the compliance deadline to February 22, 2027 and views a near-term reverse split as the only acceptable plan.
Analysis · ENSC · Life Sciences
The December 14 reverse-split vote just became easier to win. Brokers can now cast street-name shares on Proposal 2 without client instructions, materially lifting the odds of approval even if retail turnout is thin. The supplement also exposes a sequencing risk: because Nasdaq treats the Series C conversion as a change of control, the reverse split may have to be completed first to clear a $4.00 initial listing bid price, so the meeting could be adjourned and reconvened. Approval is framed as necessary to avoid delisting, with the bid-price deadline already extended to February 22, 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSC was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.23 to $2.04. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.